Meet with our product experts in one-on-one virtual sessions
Set Up a MeetingWe offer:
Dr. Reddy's offers a wide selection of anti-diabetic active pharmaceutical ingredients used in the production of formulations to treat a wide range of metabolic diseases. Catering to the needs of anti-diabetic formulators, we have been manufacturing and supplying anti-diabetic APIs for over two decades.
Meeting the needs of formulation manufacturers, Dr. Reddy's provides customized particle size distribution for Anti-diabetic APIs. We are a reliable API partner with a de-risked supply chain model and complete backward integration, ensuring timely supplies to meet your demand.
Dr. Reddy's has been recognized as one of the largest, reliable manufacturers of Anti-diabetic APIs. With a production capability of multi-tonnes per year, our APIs are part of medicines across the globe, formulated by partners around the world.
We offer a broad portfolio of APIs catering to Anti- Diabetic therapy, understanding the global demand, and supporting our customers with their launch requirements. Some of the critical classes of APIs under our Anti-diabetic portfolio include:
Glimepiride
Pioglitazone hydrochloride
Our team of process and analytical experts draw on their integrated understanding of IP, regulatory affairs, process development (API & formulation), and API manufacturing to ensure early entry into the market. This is of particular importance to select the optimal synthesis route in the context of the IP situation.
Other aspects are the solid-state forms and particle characteristics that are critical in formulation development. Therefore, extensive analytical tools and techniques such as 1H NMR, 13 C NMR, 2 D NMR, HRMS, DSC, TGA, IR, SEM, and PXRD have been used to elucidate the API structure, compare the different solid forms, and demonstrate the chemical and physical attributes of the API.
It is ensured that the APIs are free from potential genotoxic and carcinogenic impurities, and a control strategy has been defined by using the QbD approach at every step of the synthesis.
Dr. Reddy’s is well-positioned to meet the global demand for Anti-Diabetic APIs. As for many of our APIs, the key starting materials (KSM) are backward integrated today. We’ve also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
To know more about our end-to-end solutions for Anti-diabetic formulations and Dosage forms. Check out our board portfolio of Anti-Diabetic APIs here (or) Contact us at api@drreddys.com.
The major Anti-diabetic APIs are classified as:
Antidiabetic APIs act by:
The Antidiabetics Market size was USD 85.5 billion in 2022 and will grow at a CAGR of 10.7% from 2022 to 2026.
In May 2022, the FDA approved Mounjaro (also known as tirzepatide) for type 2 diabetes management and diet and exercise. This first-in-class medication has been shown to improve glucose levels and weight dramatically in clinical trials.
本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。
Join us to explore how we
can transform your API
sourcing strategy